191 related articles for article (PubMed ID: 35020836)
1. Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.
Antoszewski M; Fournier N; Ruiz Buendía GA; Lourenco J; Liu Y; Sugrue T; Dubey C; Nkosi M; Pritchard CEJ; Huijbers IJ; Segat GC; Alonso-Moreno S; Serracanta E; Belver L; Ferrando AA; Ciriello G; Weng AP; Koch U; Radtke F
Blood; 2022 Apr; 139(16):2483-2498. PubMed ID: 35020836
[TBL] [Abstract][Full Text] [Related]
2. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.
Herranz D; Ambesi-Impiombato A; Palomero T; Schnell SA; Belver L; Wendorff AA; Xu L; Castillo-Martin M; Llobet-Navás D; Cordon-Cardo C; Clappier E; Soulier J; Ferrando AA
Nat Med; 2014 Oct; 20(10):1130-7. PubMed ID: 25194570
[TBL] [Abstract][Full Text] [Related]
3. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
4. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
Choi SH; Severson E; Pear WS; Liu XS; Aster JC; Blacklow SC
PLoS One; 2017; 12(10):e0185762. PubMed ID: 29023469
[TBL] [Abstract][Full Text] [Related]
5. β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1.
Gekas C; D'Altri T; Aligué R; González J; Espinosa L; Bigas A
Leukemia; 2016 Oct; 30(10):2002-2010. PubMed ID: 27125305
[TBL] [Abstract][Full Text] [Related]
6. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.
Yashiro-Ohtani Y; Wang H; Zang C; Arnett KL; Bailis W; Ho Y; Knoechel B; Lanauze C; Louis L; Forsyth KS; Chen S; Chung Y; Schug J; Blobel GA; Liebhaber SA; Bernstein BE; Blacklow SC; Liu XS; Aster JC; Pear WS
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):E4946-53. PubMed ID: 25369933
[TBL] [Abstract][Full Text] [Related]
7. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
Sanchez-Martin M; Ferrando A
Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
[TBL] [Abstract][Full Text] [Related]
8. GATA3-Controlled Nucleosome Eviction Drives
Belver L; Yang AY; Albero R; Herranz D; Brundu FG; Quinn SA; Pérez-Durán P; Álvarez S; Gianni F; Rashkovan M; Gurung D; Rocha PP; Raviram R; Reglero C; Cortés JR; Cooke AJ; Wendorff AA; Cordó V; Meijerink JP; Rabadan R; Ferrando AA
Cancer Discov; 2019 Dec; 9(12):1774-1791. PubMed ID: 31519704
[TBL] [Abstract][Full Text] [Related]
9. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
[TBL] [Abstract][Full Text] [Related]
10. Phosphatase PRL2 promotes oncogenic NOTCH1-Induced T-cell leukemia.
Kobayashi M; Bai Y; Chen S; Gao R; Yao C; Cai W; Cardoso AA; Croop J; Zhang ZY; Liu Y
Leukemia; 2017 Mar; 31(3):751-754. PubMed ID: 27872499
[No Abstract] [Full Text] [Related]
11. How to resist Notch-targeted T-leukemia therapy: Lineage- and MYC enhancer switch.
Bayer M; Grosschedl R
Mol Cell; 2022 Mar; 82(5):884-886. PubMed ID: 35245453
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.
Durinck K; Van Loocke W; Van der Meulen J; Van de Walle I; Ongenaert M; Rondou P; Wallaert A; de Bock CE; Van Roy N; Poppe B; Cools J; Soulier J; Taghon T; Speleman F; Van Vlierberghe P
Leukemia; 2015 Dec; 29(12):2317-27. PubMed ID: 26108691
[TBL] [Abstract][Full Text] [Related]
13. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.
Rakowski LA; Garagiola DD; Li CM; Decker M; Caruso S; Jones M; Kuick R; Cierpicki T; Maillard I; Chiang MY
Cancer Res; 2013 Jan; 73(2):930-41. PubMed ID: 23161489
[TBL] [Abstract][Full Text] [Related]
14. PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.
Efimenko E; Davé UP; Lebedeva IV; Shen Y; Sanchez-Quintero MJ; Diolaiti D; Kung A; Lannutti BJ; Chen J; Realubit R; Niatsetskaya Z; Ten V; Karan C; Chen X; Califano A; Diacovo TG
Mol Cancer Ther; 2017 Oct; 16(10):2069-2082. PubMed ID: 28716817
[TBL] [Abstract][Full Text] [Related]
15. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
[TBL] [Abstract][Full Text] [Related]
16. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
17. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.
Xi M; Guo S; Bayin C; Peng L; Chuffart F; Bourova-Flin E; Rousseaux S; Khochbin S; Mi JQ; Wang J
Front Med; 2022 Jun; 16(3):442-458. PubMed ID: 34669156
[TBL] [Abstract][Full Text] [Related]
18. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
19. The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas.
Tiemessen MM; Baert MR; Schonewille T; Brugman MH; Famili F; Salvatori DC; Meijerink JP; Ozbek U; Clevers H; van Dongen JJ; Staal FJ
PLoS Biol; 2012; 10(11):e1001430. PubMed ID: 23185135
[TBL] [Abstract][Full Text] [Related]
20. Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis.
Gómez-del Arco P; Kashiwagi M; Jackson AF; Naito T; Zhang J; Liu F; Kee B; Vooijs M; Radtke F; Redondo JM; Georgopoulos K
Immunity; 2010 Nov; 33(5):685-98. PubMed ID: 21093322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
